Development and Validation of the Method Estimation for Escitolapram and Etizolam in Formulated dosage form using RP-HPLC

A refined and selective RP-HPLC method has been established and validated for the analysis of escitalopram and etizolam active pharmaceutical ingredients (APIs). The peak purity results derived from the analysis of samples using the described method suggest that the lack of co-eluting peaks alongside the primary peaks of escitalopram and etizolam confirms the specificity of the developed method for their estimation. The calibration curve exhibited a linear relationship across a concentration range of 25-150 μg/ml for escitalopram and 2.5-15 μg/ml for Etizolam, with correlation coefficients of 0.998 for both substances. The method’s accuracy was validated at levels corresponding to 80%, 100%, and 120% of the specified limit.The minimum detection limits identified were 0.1 μg/ml for escitalopram and 0.15 μg/ml for Etizolam. The minimum quantification limits established were 0.3 μg/ml for escitalopram and 0.45 μg/ml for Etizolam.